Latest News

Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

24th October 2016

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration […]

Read More
Quanta News

Quanta presents interim analysis of first 255 treatments using SC+

20th September 2016

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announced that it will present a poster at a moderated session on Friday 23rd […]

Read More
Veryan Premarket Approval

Veryan announces first patient enrolment into MIMICS-3D Registry

15th September 2016

MIMICS-3D is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Self-Expanding Stent System in the treatment of peripheral arterial disease. The Registry will evaluate safety, effectiveness and device performance within a real-world clinical population in a minimum of […]

Read More
Veryan News

Veryan Medical Announces Trial Results

13th June 2016

Veryan Medical has announced the achievement of four significant milestones in its MIMICS clinical programme: (1) The publication of the Mimics Study article; (2) The enrolment of the 200th patient in the MIMICS-2 IDE Study; (3) The first live case […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top